NICE rejects eribulin for breast cancer

The National Institute for Health and Clinical Excellence (NICE) has decided that eribulin (Halaven) should not be made available on the NHS.

Eribulin is not recommended for the treatment of breast cancer on the NHS | SCIENCE PHOTO LIBRARY
Eribulin is not recommended for the treatment of breast cancer on the NHS | SCIENCE PHOTO LIBRARY

The outcome was based on the side-effect profile of eribulin in comparison to other established available treatments.

Halaven is licensed for use as monotherapy in treating patients with locally advanced or metastatic breast cancer which has progressed after at minimum of two chemotherapeutic regimens.

Further information

NICE guidance on eribulin for breast cancer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...